Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study

Oh, MinKyung; Yoon, Jaeseung; Cho, Doo-Yeoun
October 2015
Clinical Drug Investigation;Oct2015, Vol. 35 Issue 10, p659
Academic Journal
Background and Objectives: A new biosimilar human recombinant epoetin alfa product (PDA10) has been developed by PanGen Biotech Inc., Korea. This study was planned to demonstrate the pharmacokinetic and pharmacodynamic comparability of PDA10 to an existing epoetin alfa (Eprex) after a single intravenous administration to healthy adult male volunteers. Methods: A randomized, double-blinded, single-dose, crossover study was conducted in 30 subjects. The subjects were assigned randomly to one of two sequence groups, and single doses of 100 IU/kg PDA10 or Eprex were administered intravenously on each of 2 treatment days separated by a 4-week washout period. Plasma erythropoietin concentrations were measured using an enzyme-linked immunosorbent assay and the pharmacokinetic parameters of the two treatments were compared. The time course and area under the effect curve (AUEC) of absolute reticulocyte counts were used as surrogate parameters for the pharmacodynamic evaluation. Adverse events (AEs) were recorded. Results: A total of 30 subjects were enrolled, and 27 completed the study. The geometric mean ratios (PDA10/Eprex) of erythropoietin for maximum plasma concentration ( C) and area under the plasma concentration-time curve to the last measurable concentration (AUC) after intravenous administration of 100 IU/kg were 1.00 (90 % confidence interval [CI] 0.96-1.05) and 0.96 (90 % CI 0.93-1.00). The absolute reticulocyte counts of PDA10 and Eprex were similar, as determined from the maximum reticulocyte count and AUEC values. Treatment-emergent AEs were mild and occurred in seven subjects. Conclusion: PDA10 and Eprex met the regulatory criteria for bioequivalence with respect to their pharmacokinetic profiles and pharmacodynamic actions.


Related Articles

  • Pharmacokinetic and pharmacodynamic profiles of recombinant human erythropoietin-loaded poly(lactic-co-glycolic acid) microspheres in rats. Zhou, Xiang-lian; He, Jin-tian; Du, Hui-juan; Fan, Yang-yang; Wang, Ying; Zhang, Hong-xia; Jiang, Yang // Acta Pharmacologica Sinica;Jan2012, Vol. 33 Issue 1, p137 

    Aim:To characterize the pharmacokinetic and pharmacodynamic profiles of the recombinant human erythropoietin (rhEPO)-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres in rats.Methods:The rhEPO-loaded microspheres were prepared using a solid-in-oil-in-water emulsion method....

  • AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Xue, Y.-Q.; Ma, B.-F.; Zhao, L.-R.; Tatom, J. B.; Li, B.; Jiang, L.-X.; Klein, R. L.; Duan, W.-M. // Gene Therapy;Jan2010, Vol. 17 Issue 1, p83 

    We have recently shown that intrastriatal injection of recombinant human erythropoietin (EPO) protects dopaminergic (DA) neurons in the substantia nigra (SN) from 6-hydroxydopamine (6-OHDA) toxicity in a rat model of Parkinson's disease. However, systemic administration of EPO did not protect...

  • Detection of Recombinant Epoetin and Darbepoetin Alpha after Subcutaneous Administration in the Horse. Lasne, Fran├žoise; Popot, Marie-agnes; Varlet-Marie, Emmanuelle; Martin, Laurent; Martin, Jean-Antoine; Bonnaure, Yves; Audran, Muchel; De Ceaurruz, Jacques // Journal of Analytical Toxicology;Nov/Dec2005, Vol. 29 Issue 8, p835 

    The paper proposes a direct detection method for anti-doping control of recombinant human erythropoietin (rHuEPO) abuse in racehorses. The method involves screening of plasma by an enzyme-linked immunosorbent assay specific for human EPO and confirmation in urine samples by characterization of...

  • Quality of Original and Biosimilar Epoetin Products. Brinks, Vera; Hawe, Andrea; Basmeleh, Abdul; Joachin-Rodriguez, Liliana; Haselberg, Rob; Somsen, Govert; Jiskoot, Wim; Schellekens, Huub // Pharmaceutical Research;Feb2011, Vol. 28 Issue 2, p386 

    Purpose: To compare the quality of therapeutic erythropoietin (EPO) products, including two biosimilars, with respect to content, aggregation, isoform profile and potency. Methods: Two original products, Eprex (epoetin alfa) and Dynepo (epoetin delta), and two biosimilar products, Binocrit...

  • International Nonproprietary Names. Haselbeck, Anton // WHO Drug Information;2010, Vol. 24 Issue 1, p21 

    The article discusses the biochemical properties of epoetins, which are recombinant versions of human erythropoietin. The carbohydrate structure and glycosylation process of epoetins are described. All epoetins irrespective of their International Nonproprietary Name (INN) exhibit distinct...

  • Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel). SoJeong Yi; Sung Eun Kim; Min-Kyu Park; Seo Hyun Yoon; Joo-Youn Cho; Kyoung Soo Lim; Sang-Goo Shin; In-Jin Jang; Kyung-Sang Yu // BioDrugs;2012, Vol. 26 Issue 3, p177 

    Objective: HD203 is a biosimilar of etanercept, a fusion protein of the ligand-binding portion of the human tumor necrosis factor receptor II linked to the Fc portion of human immunoglobulin Gl. Since HD203 is under clinical development, this study was conducted to compare the pharmacokinetics...

  • A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). Mcgowan, Ian; Cranston, Ross D.; Duffill, Kathryn; Siegel, Aaron; Engstrom, Jarret C.; Nikiforov, Alexyi; Jacobson, Cindy; Rehman, Khaja K.; Elliott, Julie; Khanukhova, Elena; Abebe, Kaleab; Mauck, Christine; Spiegel, Hans M. L.; Dezzutti, Charlene S.; Rohan, Lisa C.; Marzinke, Mark A.; Hiruy, Hiwot; Hendrix, Craig W.; Richardson-Harman, Nicola; Anton, Peter A. // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Objectives: The CHARM-01 study characterized the safety, acceptability, pharmacokinetics (PK), and pharmacodynamics (PD) of three tenofovir (TFV) gels for rectal application. The vaginal formulation (VF) gel was previously used in the CAPRISA 004 and VOICE vaginal microbicide Phase 2B trials...

  • Erythropoiesis stimulating agents: approaches to modulate activity. Sinclair, Angus M. // Biologics: Targets & Therapy;2013, Vol. 7, p161 

    Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may...

  • Effects of A Breast-Health Herbal Formula Supplement on Estrogen Metabolism in Pre- and Post-Menopausal Women not Taking Hormonal Contraceptives or Supplements: A Randomized Controlled Trial. Laidlaw, Maggie; Cockerline, Carla A.; Sepkovic, Daniel W. // Breast Cancer: Basic & Clinical Research;2010, Issue 4, p85 

    Introduction: Both indole-3-carbinol and dietary lignans have beneficial effects on estrogen metabolism and breast cancer risk. There is no published literature on the effects of a combination product. This study was designed to investigate the impact of a combination product on estrogen...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics